New Evidence Challenges Mifepristone: Women's Safety at Risk
Submitted by MAGA
Posted 2 hours ago
**Complications Arise Around Mifepristone: New Research Questions FDA's Commitment to Women's Safety**
In a troubling turn of events for those advocating for women’s health and informed choices, new research challenges the Food and Drug Administration's (FDA) stance on mifepristone, a drug commonly used in chemical abortions.
The findings, published by the Ethics and Public Policy Center, reveal that nearly 11% of women who undergo mifepristone abortions experience severe complications.
This alarming statistic contrasts sharply with the FDA's long-standing claim of less than 0.5% serious adverse reactions during clinical trials.
Texas Attorney General Ken Paxton recently achieved a significant legal victory, securing a $100,000 judgment against a New York doctor for illegal telehealth prescriptions of mifepristone to Texas residents.
The implications are clear: as more states seek to protect life and ensure the safety of women, the battles will intensify.
Commissioner of the FDA, Marty Makary, has seemingly dismissed calls to reevaluate mifepristone's approval by stating that he has "no plans" to impose restrictions, despite the growing body of evidence on potential risks.
Critics, including Republican legislators, are vocal about their disappointment with this approach.
Senator Josh Hawley of Missouri expressed his concerns, calling Makary's lack of urgency "exceptionally disappointing," as it suggests a troubling disregard for the emerging safety data.
The debate is further fueled by Democratic lawmakers' attempts to stifle scientific inquiry into the drug's safety.
Senator Tammy Baldwin of Wisconsin and others have pressed for continuity in mifepristone's access, echoing sentiments aligned with Planned Parenthood’s narratives.
Meanwhile, pro-life advocates are fighting back, seeking the right to inform women about potential alternatives to mifepristone.
As the legal battles unfold, it becomes increasingly evident that the issue of chemical abortions will continue to be litigated in courts across the nation.
With rising drug-related complications and an unclear path for mifepristone, the health and safety of women hang in the balance.
Demands for thorough investigations and transparency at the FDA are more crucial than ever as America grapples with these pressing moral and health questions.
As states like Texas take proactive measures, the role of the federal government and its agencies will undoubtedly come under scrutiny for their effectiveness and accountability in protecting women's health.
Sources:
justthenews.com
twitchy.com
amgreatness.com
In a troubling turn of events for those advocating for women’s health and informed choices, new research challenges the Food and Drug Administration's (FDA) stance on mifepristone, a drug commonly used in chemical abortions.
The findings, published by the Ethics and Public Policy Center, reveal that nearly 11% of women who undergo mifepristone abortions experience severe complications.
This alarming statistic contrasts sharply with the FDA's long-standing claim of less than 0.5% serious adverse reactions during clinical trials.
Texas Attorney General Ken Paxton recently achieved a significant legal victory, securing a $100,000 judgment against a New York doctor for illegal telehealth prescriptions of mifepristone to Texas residents.
The implications are clear: as more states seek to protect life and ensure the safety of women, the battles will intensify.
Commissioner of the FDA, Marty Makary, has seemingly dismissed calls to reevaluate mifepristone's approval by stating that he has "no plans" to impose restrictions, despite the growing body of evidence on potential risks.
Critics, including Republican legislators, are vocal about their disappointment with this approach.
Senator Josh Hawley of Missouri expressed his concerns, calling Makary's lack of urgency "exceptionally disappointing," as it suggests a troubling disregard for the emerging safety data.
The debate is further fueled by Democratic lawmakers' attempts to stifle scientific inquiry into the drug's safety.
Senator Tammy Baldwin of Wisconsin and others have pressed for continuity in mifepristone's access, echoing sentiments aligned with Planned Parenthood’s narratives.
Meanwhile, pro-life advocates are fighting back, seeking the right to inform women about potential alternatives to mifepristone.
As the legal battles unfold, it becomes increasingly evident that the issue of chemical abortions will continue to be litigated in courts across the nation.
With rising drug-related complications and an unclear path for mifepristone, the health and safety of women hang in the balance.
Demands for thorough investigations and transparency at the FDA are more crucial than ever as America grapples with these pressing moral and health questions.
As states like Texas take proactive measures, the role of the federal government and its agencies will undoubtedly come under scrutiny for their effectiveness and accountability in protecting women's health.
Sources:
justthenews.com
twitchy.com
amgreatness.com
Latest News